SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 15, 2024
 · 
14 min read
Pharm Country
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
March 8, 2024
 · 
14 min read
Drug Development
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
March 1, 2024
 · 
13 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
February 28, 2024
 · 
20 min read
Pharm Country
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)Newly issued patents extend exclusivity of ublituximab through 2042
February 27, 2024
 · 
15 min read
Pharm Country
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country
February 26, 2024
 · 
13 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business UpdateConference call to be held Wednesday, February 28, 2024, at 8:30 AM ET
February 23, 2024
 · 
1 min read
Drug Development
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 20, 2024
 · 
14 min read
Business
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
February 12, 2024
 · 
8 min read
Business
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 10, 2024
 · 
15 min read
Business
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 9, 2024
 · 
10 min read
Business
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
January 9, 2024
 · 
5 min read
Pharm Country
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT
January 5, 2024
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceFireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET
November 27, 2023
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) ConferenceFireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET
November 3, 2023
 · 
1 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 1, 2023
 · 
19 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS